1. Home
  2. HRMY vs BHVN Comparison

HRMY vs BHVN Comparison

Compare HRMY & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • BHVN
  • Stock Information
  • Founded
  • HRMY 2017
  • BHVN 2013
  • Country
  • HRMY United States
  • BHVN United States
  • Employees
  • HRMY N/A
  • BHVN N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • BHVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HRMY Health Care
  • BHVN Health Care
  • Exchange
  • HRMY Nasdaq
  • BHVN Nasdaq
  • Market Cap
  • HRMY 1.9B
  • BHVN 1.7B
  • IPO Year
  • HRMY 2020
  • BHVN 2017
  • Fundamental
  • Price
  • HRMY $26.87
  • BHVN $15.31
  • Analyst Decision
  • HRMY Strong Buy
  • BHVN Strong Buy
  • Analyst Count
  • HRMY 10
  • BHVN 14
  • Target Price
  • HRMY $51.30
  • BHVN $49.23
  • AVG Volume (30 Days)
  • HRMY 1.0M
  • BHVN 2.4M
  • Earning Date
  • HRMY 10-28-2025
  • BHVN 11-11-2025
  • Dividend Yield
  • HRMY N/A
  • BHVN N/A
  • EPS Growth
  • HRMY 58.41
  • BHVN N/A
  • EPS
  • HRMY 3.10
  • BHVN N/A
  • Revenue
  • HRMY $772,527,000.00
  • BHVN N/A
  • Revenue This Year
  • HRMY $19.94
  • BHVN N/A
  • Revenue Next Year
  • HRMY $16.65
  • BHVN $2,195.07
  • P/E Ratio
  • HRMY $8.72
  • BHVN N/A
  • Revenue Growth
  • HRMY 17.74
  • BHVN N/A
  • 52 Week Low
  • HRMY $26.26
  • BHVN $12.79
  • 52 Week High
  • HRMY $41.61
  • BHVN $55.70
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 27.45
  • BHVN 52.61
  • Support Level
  • HRMY $26.56
  • BHVN $14.32
  • Resistance Level
  • HRMY $27.48
  • BHVN $16.24
  • Average True Range (ATR)
  • HRMY 1.01
  • BHVN 0.87
  • MACD
  • HRMY -0.25
  • BHVN 0.14
  • Stochastic Oscillator
  • HRMY 8.99
  • BHVN 63.91

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Share on Social Networks: